Sarepta soars again, Prosensa slides further

The divergence of fortunes for Prosensa (RNA -2.9%) and Sarepta Therapeutics (SRPT +11.8%) continues today, as investors and analysts digest Friday's drisapersen data.

SRPT is up double-digits for a second session, bringing gains since Thursday to ~31%.

Meanwhile, RNA extends its losses as Wedbush says the company's call "suggests the anticipated causes for concern with [DEMAND-III] did not result in its failure, which ... calls into question drisapersen's therapeutic activity.”

Previous coverage

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs